Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax + selinexor + chidamide in relapsed/refractory AML
ChiCTR2600125924Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lisaftoclax, selinexor and tucidinostat in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoint: Composite Complete Remission Rate. Started Jun 2026; status: recruiting.
02
Drugs
lisaftoclaxselinexortucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600125924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125924.